FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
Lotimatou avorago bare									
hours per response:	0.5								
p soponoo.	0.0								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  LONGENECKER JOHN P PHD  (Last) (First) (Middle)  C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 100						Issuer Name and Ticker or Trading Symbol     Pacira Pharmaceuticals, Inc. [ PCRX ]      The symbol of Earliest Transaction (Month/Day/Year)     106/30/2014      If Amendment, Date of Original Filed (Month/Day/Year)										X Di O be Individuation	app rect ffice elow	or r (give title r)	p Filii	10% O Other ( below)	wner (specify Applicable	
(Street) PAR SIPI			07054 (Zip)															Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
1. Title of Security (Instr. 3)  2. Tran Date (Month.						Exe if a	2A. Deemed Execution Date, if any (Month/Day/Year			Transaction Dis			ecurities Acquired ( posed Of (D) (Instr. 5					cially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	V Amou		nt (A) or (D)		Price	Re Tra	port insa		(11130. 4)		(111301. 4)	
Common Stock 06/30/20										M		1,0	00 A		\$29	9.9	1,000			D		
Common Stock 06/30/20						014				S <sup>(1)</sup>		1,0	00 D \$		\$91	1.6	0		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	emed ion Date, /Day/Year)	4. Transac Code (Ir 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Ex	Date Exer piration I onth/Day	ate		7. Title and Amount of Securities Underlying Derivative Security (Ins and 4)		tr. 3	8. Price of Derivati Security (Instr. 5	ve '	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dai Exe	ite ercisable		oiration e	Title	or Nu of	nount mber ares							
Stock Option (Right to Buy)	\$29.9	06/30/2014			M			1,000		(2)	06/	11/2023	Commo Stock		,000	\$0		5,000		D		

## Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The option shares vest in 12 equal successive monthly installments over the 12-month period following the date of grant, subject to the reporting person's continued service as a director.

/s/ James Scibetta, Attorneyin-Fact 07/01/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.